NSE · GLAND · Pharmaceuticals
Gland Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,262 Cr with net profit ₹420 Cr — a 33.33% net margin, versus 26.14% the period before.
Shareholding
As of 2026-06-30
- Promoter51.77%
- Public9.05%
- FII8.74%
- DII30.44%
1,08,266 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.64× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #3 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,319 Cr | 84.56 | 22.04 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,933 Cr | 160.96 | 9.52 | 23.33% | 19.37% |
| Gland Pharma Limited(this company) | ₹41,520 Cr | 113.07 | 4 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹24,811 Cr | 100.55 | 19.25 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,279 Cr | 113.33 | 5.37 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,056 Cr | 66.76 | 4.88 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,793 Cr | 50.54 | 4.55 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,719 Cr | 28.05 | 3.88 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹5,952 Cr | 47.1 | 6.38 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,827 Cr | 141.35 | 4.04 | 8.95% | 11.15% |
AI analysis
AI-generated · google/gemini-2.5-flashGland Pharma Limited is listed on the Indian markets with a market capitalization of Rs 40565 Cr. The company reported revenue of Rs 5830.11 Cr and an EPS of Rs 63.29. Its debt-to-equity ratio is 0.04.
Positives
- +The company has a low debt-to-equity ratio of 0.04.
- +Promoter holding is stable at 51.7665% as of June 30, 2026.
- +The company has not reported any promoter share pledges.
Negatives
- −Revenue growth for the last year was -0.8%, indicating a contraction in revenue.
- −The trailing twelve-month P/E ratio is high at 110.47.
- −The Return on Equity (ROE) is 9.92%, which is below 10%.
Financial Performance
Gland Pharma Limited's revenue for the last year was Rs 5830.11 Cr, marking a growth of -0.8%. The company's profit margin stood at 15.98%. Over the past year, the company's EPS was Rs 63.29. The latest annual net profit recorded was Rs 698.526 Cr in Mar 2025.
Profitability & Returns
The company's Return on Equity (ROE) is 9.92% and Return on Capital Employed (ROCE) is 14.02%. The profit margin for Gland Pharma Limited is 15.98%. The trailing twelve-month EPS is Rs 63.29.
Balance Sheet
Gland Pharma Limited has a book value of Rs 627.91 per share. The debt-to-equity ratio is low at 0.04, indicating a limited reliance on debt financing. The company has no reported promoter share pledges.
Ownership & Pledges
As of June 30, 2026, promoters held 51.7665% of the shares. DIIs held 30.4428%, FIIs held 8.74%, and the public held 9.0507%. The total number of shareholders was 108266. There are no reported promoter share pledges.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.